Cargando…
Reflections after TWILIGHT study: a new era in secondary prevention without aspirin?
Dual antiplatelet therapy (DAPT) is mandatory in patients undergoing percutaneous coronary interventions (PCIs), but carries an increased bleeding risk which must be weighed over the expected antithrombotic benefit. In recent years, DAPT optimization strategy has been enriched by the concept of earl...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503404/ https://www.ncbi.nlm.nih.gov/pubmed/34650353 http://dx.doi.org/10.1093/eurheartj/suab087 |